TG 6002

Drug Profile

TG 6002

Alternative Names: TG6002; VV-TK-RR-FCU1; VVWR-TK-RR-Fcu1

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transgene
  • Developer Assistance Publique Hopitaux de Paris; Transgene
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 21 Mar 2018 Transgene files an IND application for phase I trial in gastrointestinal adenocarcinoma before March 2018
  • 21 Mar 2018 Transgene plans a phase I trial for Gastrointestinal adenocarcinoma
  • 26 Oct 2017 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater) in France (IV-infusion) (NCT03294486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top